Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and ...

芝加哥和德克萨斯州沃思堡 - Actuate Therapeutics, Inc. (NASDAQ: ACTU)，一家专注于开发癌症治疗方法的生物制药公司，宣布美国食品和药物管理局(FDA)已授予其药物elraglusib用于治疗尤文氏肉瘤的罕见儿科疾病designation。 尤文氏肉瘤是一种高度转移的骨癌，主要影响儿童和青少年，25%的患者在诊断时已出现转移性疾病。FDA的这一designat ...

About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s ...

Actuate, a global provider of vision-based AI monitoring solutions, has announced the appointment of Ken Francis as CEO.

Francis will lead Actuate’s continued global expansion, strengthen its channel partnerships, and advance its position as a ...

Actuate Therapeutics said its treatment for Ewing sarcoma was granted rare pediatric-disease designation from the Food and Drug Administration. Chief Executive Daniel Schmitt said early clinical data ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

This page features the latest news about the Actuate Therapeutics stock. Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development Companies will discuss how Lantern's AI ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment ...